Research Analysts’ Recent Ratings Changes for Johnson & Johnson (JNJ)

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

  • 4/17/2019 – Johnson & Johnson had its price target raised by analysts at BMO Capital Markets from $154.00 to $157.00. They now have an “outperform” rating on the stock.
  • 4/17/2019 – Johnson & Johnson had its price target raised by analysts at Credit Suisse Group AG from $151.00 to $152.00. They now have an “outperform” rating on the stock.
  • 4/17/2019 – Johnson & Johnson had its price target raised by analysts at Raymond James from $145.00 to $147.00. They now have an “outperform” rating on the stock.
  • 4/17/2019 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $134.00 to $145.00. They now have an “equal weight” rating on the stock.
  • 3/27/2019 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $155.00 price target on the stock. According to Zacks, “J&J’s sales growth accelerated in 2018 backed by abovemarket sales growth in the Pharmaceutical segment and improving performance in Medical Devices unit. However, J&J’s guidance for 2019 sales growth was below expectations due to Pharma generic/biosimilar headwinds, which will hurt sales by $3 billion. However, J&J sales and earnings growth is expected to accelerate in 2020 supported by drug launches, successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J’s shares have outperformed the industry this year. Headwinds like biosimilar/generic competition and pricing pressure remain.”
  • 2/25/2019 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc from $139.00 to $147.00. They now have a “neutral” rating on the stock.

Shares of Johnson & Johnson stock opened at $137.52 on Monday. The firm has a market capitalization of $368.95 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 2.38 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.07. The firm had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 35.79%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.06 EPS. Analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Evolution Wealth Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $40,000. Crewe Advisors LLC grew its holdings in Johnson & Johnson by 75.0% during the 4th quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after acquiring an additional 150 shares during the last quarter. Horan Securities Inc. grew its holdings in Johnson & Johnson by 122.3% during the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after acquiring an additional 241 shares during the last quarter. First Bank & Trust grew its holdings in Johnson & Johnson by 30.4% during the 1st quarter. First Bank & Trust now owns 399 shares of the company’s stock worth $56,000 after acquiring an additional 93 shares during the last quarter. Finally, Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth about $58,000. 67.32% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is a Roth IRA?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.